Scientists are testing CRISPR gene editing as a potential HIV cure after successfully removing the virus from infected cells ...

Did patients in a failed HIV vaccine trial halted in 2007 become more susceptible to the virus due to the adenoviral vector used to deliver the experimental vaccine? Researchers have speculated this ...

New findings have disproved a leading explanation for why an experimental HIV vaccine made subjects more susceptible to the virus, reopening the door for further HIV vaccine efforts based on similar ...

CHICAGO--(BUSINESS WIRE)--Genetic Immunity, a leader in plasmid DNA-based immunotherapies, and VectorBuilder, a global specialist in gene delivery solutions, announced a strategic partnership to ...

At least 30 vaccines for HIV are in clinical trials to either prevent HIV infection or suppress the development of AIDS. James Laufenberg, president and CEO of ImmunoGenetix Therapeutics, is working ...

MOSCOW, July 26. /TASS/. Experts of Russia’s Federal Medical and Biological Agency (FMBA) are now developing a new medicine against Human Immunodeficiency Virus (HIV), based on lentiviral vector, the ...

A number of trials of various subtype B canarypox–HIV vector primes and boosters containing subunit glycoprotein 120 or 160 (gp120 or gp160) established the prime–boost concept as a candidate for ...

Renowned for its focus on developing cutting-edge DNA-based vaccines, Genetic Immunity has built an industry-leading team to deliver its lead candidate, a plasmid DNA HIV vaccine, into a Phase 3 trial ...